Form 4: Palisade Bio Director Receives RSU Grant

Director Jordan Michael Zwick was granted 336,904 restricted stock units by Palisade Bio, Inc.

Summary

• Director Jordan Michael Zwick acquired 336,904 restricted stock units (RSUs) on June 10, 2026.
• Each RSU represents a contingent right to receive one share of common stock.
• The units are subject to a service-based vesting schedule over three years.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no immediate impact on company operations or financial health.

Positives

• Alignment of director interests with shareholders through equity-based compensation.

Negatives

• Potential future dilution of existing shareholders upon the vesting and issuance of the underlying common stock.

Risks

• Vesting is contingent upon the director's continuous service with the issuer.

Future Outlook

The RSUs will vest in three equal annual installments starting on June 10, 2027, subject to continued service.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practice in the biotechnology sector to ensure long-term alignment between leadership and company performance.

Comparison to Industry Standards

• The use of three-year service-based vesting schedules is consistent with standard equity compensation practices for board members in small-cap biotech firms.

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual conversion of RSUs into common stock.

Next Steps

• Vesting of the first installment of RSUs on June 10, 2027.

Key Dates

Keywords

Palisade Bio, PALI, Form 4, Insider Trading, Restricted Stock Units, Director Compensation